quantisnow
FeedTopReportsPricing
⌘K
Live feed
21:06:04·49d
INSIDERFiling
Emergent BioSolutions Inc. logo

EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 8,199 shares, decreasing direct ownership by 7% to 104,108 units (SEC Form 4)

EBS· Emergent BioSolutions Inc.
Health Care
Original source

Companies

  • EBS
    Emergent BioSolutions Inc.
    Health Care

Recent analyst ratings

  • Dec 30UpdateH.C. Wainwright$15.00
  • Aug 22UpdateRodman & Renshaw$16.00
  • Mar 7UpdateThe Benchmark Company$5.00
  • Nov 20UpdateJP Morgan-
  • Aug 29UpdateThe Benchmark Company-
  • Apr 10UpdateThe Benchmark Company$22.00

Related

  • SEC1d
    SEC Form DEFA14A filed by Emergent BioSolutions Inc.
  • PR7d
    Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
  • PR7d
    Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
  • SEC7d
    SEC Form DEFA14A filed by Emergent BioSolutions Inc.
  • SEC7d
    SEC Form DEFA14A filed by Emergent BioSolutions Inc.
  • PR14d
    Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
  • SEC14d
    SEC Form SCHEDULE 13G filed by Emergent BioSolutions Inc.
  • PR16d
    Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022